Related Experiment Videos
Bromfenac (Duract)-associated hepatic failure requiring liver transplantation
E B Hunter1, P E Johnston, G Tanner
1Department of Medicine, Vanderbilt University, Nashville, Tennessee 37232-2279, USA.
The American Journal of Gastroenterology
|August 13, 1999
Abstract:
Bromfenac sodium (Duract) is a phenylacetic acid-derived nonsteroidal anti-inflammatory agent introduced in the United States in 1997 and withdrawn in 1998. We describe the first case of fulminant hepatic failure associated with this agent treated successfully with liver transplantation. Similarities to hepatotoxicity with related agents is discussed.